Results from the DETECT I study.

Open-label trial compares 2 first-line therapies.

Dual-based atazanavir/ritonavir regimen offers superior alternative for virologically suppressed adults with HIV.

Study offers rationale for improving guideline-recommended questionnaires.

The effects may be passed on to future generations.

Aerobic exercise can help address a problem often neglected in clinical practice.

Findings do not support HPV vaccination of HIV-infected adults age 27 or older.

Clinicians hold the key to better HPV vaccination coverage in the United States.

ZIKV may persist in semen for over 6 months, but viral shedding appears short-lived.

Both are likely to be underreported as coexisting problems later in life.

6- to 9-month gaps between primary care visits may be viable for select patients.

Recent national data highlight HIV screening needs persist.

Researchers call for a multidisciplinary treatment approach.

More urinary complications, longer stays, but similar cardiac outcomes vs no catheter.